PCSK9 Inhibitors

Pradeep Natarajan; Sekar Kathiresan

doi:10.1016/j.cell.2016.05.016

PCSK9 Inhibitors

Cell. 2016 May 19;165(5):1037. doi: 10.1016/j.cell.2016.05.016.

Authors

Pradeep Natarajan¹, Sekar Kathiresan²

Affiliations

¹ Center for Human Genetic Research and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA 02114, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02115, USA.
² Center for Human Genetic Research and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA 02114, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address: skathiresan@partners.org.

PMID: 27203103
DOI: 10.1016/j.cell.2016.05.016

Abstract

Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein (LDL) receptors. These therapies increase LDL receptors on the cell surface and reduce plasma LDL cholesterol. Both therapies are approved to lower LDL cholesterol, a causative agent for atherosclerotic cardiovascular disease.

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents / therapeutic use*
Cholesterol, LDL / blood
Humans

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
Cholesterol, LDL
evolocumab
alirocumab